Sunit Talapatra
Partner
Dr. Sunit Talapatra鈥檚 practice focuses on the intellectual property needs of diverse technology clients spanning pharmaceuticals, diagnostics, agriculture, food and nutrition, and medical devices. He also has a unique perspective on European companies with ties to the United States, having lived in the Netherlands and frequently returning to the continent. He is a partner in the firm鈥檚 Chemical, Biotechnology & Pharmaceutical, and Private Equity & Venture Capital Practices as well as the Health Care & Life Sciences Sector.
In addition to patent counseling and prosecution matters, Sunit has argued several cases before the United States Patent Trial and Appeal Board, notably orchestrating a successful defense in the聽“1st-Ever” Pharma AIA Ruling (Amneal Pharma Inc v. Supernus Pharma Inc.). Some of his exemplary patent cases include聽Chatterjee v. Tabor聽(interference proceeding re DNA polymerase);聽Keygene NV v. Floragenex, Inc. (patent infringement action); and聽Biota Scientific Ltd. v. Kappos聽(appeal of USPTO decision re obviousness of pharmaceutical formulation).
Awards and Recognition
- Recognized in IAM Patent 1000 鈥 The World鈥檚 Leading Patent Practitioners (2024)
Presentations and Publications
- 鈥淕eneral Counsel Speak: Building a Forward-Thinking IP Strategy,鈥 麻豆传媒鈥檚 Annual IP Conference (October 2022)
- 鈥淧erspectives on the New Normal,鈥 麻豆传媒鈥檚 Annual IP Conference (October 2021)
- “Patenting Strategies: The Counsel (Corporate and Private),鈥 FCBA Global Outreach Series (October 2016)
- “IP Management: Getting It Right in Both Europe and the US,” Innovation for Health Conference (February 2014)
- “Legal Issues Facing Health Companies in the US Market,” Health & Technology Conference (September 2013)
- “Hindsight is 20/20: Entrepreneurs Share Viewpoints on What They Wish They’d Known,” Nanotech Commercialization Conference (April 2013)
- “Intellectual Property,” Wharton Business Law Conference (February 2013)
- “Intellectual Property Life Cycle Management鈥擳houghts to Consider in Strategic Patent Protection,” American Chemical Society (August 2012)
- “Risk vs Value: The Impact of Nanotechnology Environmental Health Safety (EHS) on Business Decisions,” Nanotech Commercialization Conference (April 2012)
- “What’s ‘natural’ about natural resources? Implications for your IP,” American Chemical Society (March 2011)
- Talapatra S, Bent S, The Art of Negotiating with U.S. Patent Examiners, A.I.P.P.I. 56(2), (2011)
- “Negotiating a patent: the art of Examiner interviews,” American Chemical Society (August 2010)
- Talapatra S, Thompson CB, et al., Elongation Factor-1 alpha Is a Selective Regulator of Growth Factor Withdrawal and ER Stress- induced Apoptosis, Cell Death Differ., 9(8), 2002, 856-61
- Karnauskas R, Talapatra S, and Rudin C, et al., Bcl-xL and Akt Cooperate to Promote Leukemogenesis In Vivo, Oncogene, 22(5), 2003, 688-98
Thought Leadership
Sunit has authored several legal and scientific publications and is frequently quoted in聽FDA Week听补苍诲听Inside Health Policy. He also regularly lectures on patent matters, most recently at the 2016 FCBA Global Outreach Series (Paris).
21st Annual IP Conference
IAM Recognizes 麻豆传媒 Attorneys and Jurisdictions in 2025 Edition of IAM Patent 1000: The World鈥檚 Leading Patent Practitioners
